Please login to the form below

Tagrisso

This page shows the latest Tagrisso news and features for those working in and with pharma, biotech and healthcare.

In 2020, oncology growth was up by 23% to $11.45bn, with the top-selling product being AZ’s EGFR-tyrosine kinase inhibitor Tagrisso (osimertinib).

AZ is expecting late-stage COVID-19 vaccine data this year

For the year to date, AZ’s oncology franchise has grown by 24% to $8.18bn, driven by strong growth of its EGFR tyrosine kinase inhibitor Tagrisso (Osimertinib) and immunotherapy Imfinzi
Janssen’s EGFR-targeting treatment regimen shows early benefit in lung cancer

In a group of 45 patients who had relapsed following treatment with AstraZeneca’s Tagrisso (osimertinib), Janssen’s combination treatment produced a 36% ORR, with one complete response and 15 partial ... The recommended dose is now being studied in a
AZ’s Tagrisso cuts risk of EGFR-positive NSCLC spreading to the brain

AstraZeneca’s Tagrisso cuts the risk of EGFR-positive lung cancer patients developing brain metastases, according to new data revealed by the company on Saturday. ... Tagrisso should become the standard of care in the adjuvant setting, just as it is
AstraZeneca escapes pandemic impact as new drugs bolster revenues

Tagrisso (osimertinib), Imfinzi (durvalumab) and Lynparza (olaparib).
Merck gets first approval for MET inhibitor tepotinib in Japan

Other rivals include AstraZeneca with small-molecule candidate savolitinib in mid-stage testing for NSCLC patients who have progressed after treatment with its EGFR inhibitor Tagrisso (osimertinib) as well as in ... combination. MET is known as a

More from news
Approximately 29 fully matching, plus 57 partially matching documents found.

20 for 2020 – Five pharma companies to watch

Cancer therapies Tagrisso (osimertinib) – now AZ’s top-selling drug – Lynparza (olaparib) and Imfinzi (durvalumab) are already gathering momentum, as they rack up additional indications that extend their use and there ... Tagrisso’s growth as it
Leading AstraZeneca’s return to growth in Europe

Now the business has two particularly strong growth drivers: emerging markets, most especially China, and oncology, where a triumvirate of drugs – Tagrisso, Imfinzi and Lynparza – have hit a major growth phase. ... Two leading examples of this are
AstraZeneca’s oncology renaissance

Eight years on, three new oncology drugs are proving to be the driving force for the new AstraZeneca: small molecule, targeted lung cancer drug Tagrisso (osimertinib) and ovarian cancer treatment Lynparza ... EvaluatePharma forecasts that Lynparza (now co
China: AstraZeneca’s new engine for growth and innovation

In March 2017, AZ’s targeted lung cancer drug Tagrisso was one of the first medicines to gain approval through the Chinese Food and Drug Administration (CFDA)’s Priority Review pathway, ... Liang had been instrumental in building up the company’s
Biopharma's Future: Made in China

targeted lung cancer drug Tagrisso and diabetes treatment Forxiga.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Add my company

Virtual congresses: video thrilled the cardio tsar: Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?: The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.: Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....